• Our offerings
    • Market Access Strategy, HTA, and Health Economics
    • Nordic RWE & Evidence Generation
    • AI & Dashboard Solutions
    • Policy Shaping & Life Science Consulting
  • Our work
  • The latest
  • Our people
  • Careers
  • Contact us

NICE recommends cemiplimab for recurrent or metastatic cervical cancer

NICE recommends first new NHS treatment in over 20 years for women with resistant ovarian cancer

Leveraging Nordic data & insights to support your Market Access goals.

NHTA Copenhagen
Nelson Mandelas Allé 14, 2450 Copenhagen SV, Denmark

NHTA Stockholm
Vasagatan 10, 5th floor, 111 20 Stockholm, Sweden

Contact us

+45 44 222 777
CVR: 39842882

+46 70-322 66 65
Org.nr: 559438-4207

contact@nhta.com

Navigation

  • Our offerings
  • Our work
  • The latest
  • Our people
  • Careers
  • Contact us

Follow us on LinkedIn

LinkedIn
  • Data Protection Policy
  • Cookie Policy